FSH-R : Diagnostic Application for Localized Tumors in Cancerology
Not Applicable
Terminated
- Conditions
- Cancer
- Registration Number
- NCT02860481
- Lead Sponsor
- Institut Curie
- Brief Summary
FRACTal study is the first exploration of detection of FSHR as a blood biomarker for the diagnosis of cancer.
A first cohort will explore several common (e.g. breast, prostate) or rare (e.g. uveal melanoma) cancers, that are frequently treated at Institut Curie. This first cohort will include n=10 patients per histological type except for breast cancer (n=50). 100 patients are expected in this cohort.
A second cohort will explore the more promising histological type (if any) in term of incidence of detection. 100 patients are expected for this second cohort.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 95
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method sensitivity of blood FSH R detection in cancer patients end of the study, up to two years
- Secondary Outcome Measures
Name Time Method comparison of blood FSH-R with blood from healthy donor end of the study, up to two years variability of blood FSH-R in the same tumoral type and between different tumoral types end of the study, up to two years
Trial Locations
- Locations (2)
Institut Curie
🇫🇷Paris, France
Centre René Huguenin
🇫🇷Saint Cloud, France
Institut Curie🇫🇷Paris, France